16-May-2024
Paulson & Co's top buy and sells in Q1
Seeking Alpha News (Thu, 16-May 8:21 AM ET)
TipRanks (Mon, 13-May 8:01 AM ET)
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Globe Newswire (Tue, 7-May 7:00 AM ET)
Madrigal Statement on the Passing of Dr. Stephen Harrison
Globe Newswire (Wed, 24-Apr 4:00 PM ET)
Globe Newswire (Tue, 23-Apr 8:00 AM ET)
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 16-Apr 4:05 PM ET)
Globe Newswire (Tue, 9-Apr 8:00 AM ET)
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Globe Newswire (Mon, 18-Mar 11:58 PM ET)
Madrigal Pharmaceuticals Announces Proposed Public Offering
Globe Newswire (Mon, 18-Mar 4:04 PM ET)
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Madrigal Pharmaceuticals trades on the NASDAQ stock market under the symbol MDGL.
As of May 16, 2024, MDGL stock price climbed to $217.17 with 225,465 million shares trading.
MDGL has a beta of 1.72, meaning it tends to be more sensitive to market movements. MDGL has a correlation of 0.11 to the broad based SPY ETF.
MDGL has a market cap of $4.63 billion. This is considered a Mid Cap stock.
In the last 3 years, MDGL stock traded as high as $322.67 and as low as $52.33.
The top ETF exchange traded funds that MDGL belongs to (by Net Assets): VTI, VB, IWM, XBI, VBR.
MDGL has underperformed the market in the last year with a price return of -25.2% while the SPY ETF gained +29.6%. MDGL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.3% and +3.1%, respectively, while the SPY returned +5.6% and +5.7%, respectively.
MDGL support price is $203.62 and resistance is $219.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDGL stock will trade within this expected range on the day.